160
Participants
Start Date
November 30, 2025
Primary Completion Date
February 28, 2029
Study Completion Date
February 28, 2030
Rituximab (R)
1000 mg at weeks 0 and 2 followed by 1000 mg every 6 months
Eculizumab (Soliris®)
900 mg weekly for 4 weeks, followed by 1200 mg every 2 weeks
Ravulizumab
"* 40 to \< 60 kg: 2400 mg~* 60 to \< 100 kg: 2700 mg~* 100 kg: 3000 mg as an induction dose, followed by~* 40 to \< 60 kg: 3000 mg~* 60 to \< 100 kg: 3300 mg~* 100 kg: 3600 mg Every 8 weeks starting 15 days after loading dose"
Satralizumab
120 mg at Weeks 0, 2, 4, followed by 120 mg every 4 weeks
Inebilizumab
300 mg on Day 1 and Day 15, followed by 300 mg every 6 months
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Charité - Universitätsmedizin Berlin, Berlin
Patient-Centered Outcomes Research Institute
OTHER
Charite University, Berlin, Germany
OTHER
The Sumaira Foundation
UNKNOWN
Massachusetts General Hospital
OTHER